Lamzede
Payments companies reported to CMS as associated with Lamzede. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lamzede, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lamzede
These are the largest totals companies reported as associated with Lamzede. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Marianne Mann | Highland, MD | Internal Medicine | $139,200.00 |
| Qais Abu Ali | Canton, OH | Internal Medicine | $35,875.00 |
| Can Ficicioglu | Philadelphia, PA | Clinical Genetics (M.D.) | $24,040.84 |
| Donna Griebel | Lawrence, KS | Internal Medicine | $22,912.50 |
| Priya Kishnani | Durham, NC | Pediatrics | $10,695.00 |
| Monica Penon Portmann | San Francisco, CA | Pediatrics | $9,265.80 |
| Regina Zambrano | New Orleans, LA | Clinical Genetics (M.D.) | $9,159.78 |
| Robert Hopkin | Cincinnati, OH | Clinical Genetics (M.D.) | $9,067.03 |
| Rabi Hanna | Cleveland, OH | Pediatric Hematology-Oncology | $7,640.16 |
| Raphael Schiffmann | Dallas, TX | Neurology With Special Qualifications In Child Neurology | $6,930.58 |
Prescribed Lamzede?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.